Clinical and translational gastroenterology · 2026
Patients With Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-Like Peptide-1 Receptor Agonist Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chaudhry Ezan, Kakadiya Payal, Vaughn Hayden, Gray Simon, Hansen Jonathan J, Haydek John P, Jain Animesh, Long Millie D, Herfarth Hans H, Barnes Edward L
Аннотация
INTRODUCTION: High bowel frequency after ileal pouch-anal anastomosis (IPAA) causes significant symptom burden. We aimed to evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in this setting.
METHODS: We conducted a retrospective cohort study of patients with previous IPAA for ulcerative colitis who were treated with a GLP-1 RA (n = 20). Daily bowel frequency at baseline and 12 weeks after GLP-1 RA initiation was assessed. We also assessed the proportion of patients achieving ≥30% reduction in bowel frequency and ≤8 bowel movements per day.
RESULTS: The median daily bowel frequency decreased from 9.0 (interquartile range [IQR], 6.0-12.5) at baseline to 6.0 (IQR, 5.0-8.1) at the 12-week follow-up ( P < 0.01). Overall, 7 of 20 patients achieved a ≥30% reduction in bowel frequency, and 15 of 20 had ≤8 bowel movements per day.
DISCUSSION: In this retrospective cohort, we provide further evidence for the potential role of GLP-1 RAs in the management of high bowel frequency after IPAA.
METHODS: We conducted a retrospective cohort study of patients with previous IPAA for ulcerative colitis who were treated with a GLP-1 RA (n = 20). Daily bowel frequency at baseline and 12 weeks after GLP-1 RA initiation was assessed. We also assessed the proportion of patients achieving ≥30% reduction in bowel frequency and ≤8 bowel movements per day.
RESULTS: The median daily bowel frequency decreased from 9.0 (interquartile range [IQR], 6.0-12.5) at baseline to 6.0 (IQR, 5.0-8.1) at the 12-week follow-up ( P < 0.01). Overall, 7 of 20 patients achieved a ≥30% reduction in bowel frequency, and 15 of 20 had ≤8 bowel movements per day.
DISCUSSION: In this retrospective cohort, we provide further evidence for the potential role of GLP-1 RAs in the management of high bowel frequency after IPAA.